Actelion from Allschwil BL makes breakthrough with new medicine
星期一, 30.04.2012

Actelion from Allschwil BL makes breakthrough with new medicine

Macitentan, a new medicine for the treatment of pulmonary hypertension, has proved safe and effective in a broad-based long-term study and can now be filed for worldwide registration and approval for marketing.

Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: “I am extremely pleased with the outstanding SERAPHIN results. We are committed to working with the Health Authorities to bring this potentially important advancement in PAH to patients as soon as possible. Submission of the registration dossier to Health Authorities worldwide is expected by the fourth quarter of 2012.”

 

Lewis J. Rubin, M.D., Emeritus Professor, University of California, San Diego and Senior Advisor on SERAPHIN commented: “With this well-designed PAH study, Actelion pursued an ambitious goal to focus on outcome benefits as the primary endpoint. The impressive results of this landmark study are setting a new standard in how to conduct studies in this devastating disease.”

 

 

For more information, please refer to www.actelion.com

<- Back to: Business Development and Life Science News in Basel, Switzerland